Perceived risk of LSD varies with age and race: evidence from 2019 United States cross-sectional data.
Nicholas L. Bormann, Andrea N Weber, Benjamin Miskle, Nicole Woodson-DeFauw, Stephan Arndt, Alison C Lynch
Social Psychiatry and Psychiatric Epidemiology October 1, 2023 DOI: 10.1007/s00127-023-02448-6 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Cross-sectional survey Peer reviewed |
|---|---|
| Sample size | 41,679 |
| Population | Respondents to the 2019 National Survey of Drug Use and Health |
| Topics | LSD |
| Keywords | Healthcare disparities Illicit drugs Substance use Psychedelics hallucinogens Entheogens Treatment gaps Care inequalities Risk assessment Safety |
| Citations | 6 |
| Key findings | White respondents and those reporting more than one race perceived significantly lower risk from LSD than other racial and ethnic groups, and perceived risk increased with age. |
Abstract
Psychedelics are being explored for their potential therapeutic benefits across a wide range of psychiatric diagnoses and may usher in a new age in psychiatric treatment. There is stigma associated with these currently illegal substances, and use varies by race and age. We hypothesized that minoritized racial and ethnic populations, relative to White respondents, would perceive psychedelic use as riskier. Using 2019 cross-sectional data from the National Survey of Drug Use and Health, we conducted a secondary analysis of 41,679 respondents. Perceived risk of heroin was used as a surrogate for overall risk of illegal substance use; heroin and lysergic acid diethylamide were the only substances queried this way in the sample. A majority regarded lysergic acid diethylamide (66.7%) and heroin (87.3%) as a great risk if used once or twice. There were clear differences by race, with White respondents and those indicating more than one race having significantly lower perceived risk of lysergic acid diethylamide than respondents from other groups. Perceived risk of use also significantly increased with age. Perceived risk of lysergic acid diethylamide is unevenly distributed across the population. Stigma and racial disparities in drug-related crimes likely contribute to this. As research into potential therapeutic indications for psychedelics continues, perceived risk of use may change.
Comparable studies
Other cross-sectional and survey studies on LSD, most cited first.
Citations in the library
Cited by 4
- Perceived Risk of Trying Lysergic Acid Diethylamide in the United States from 2015 to 2019: Are Americans Assessing Lysergic Acid Diethylamide's Risk Profile More Favorably? Psychedelic Medicine June 1, 2024
- The Rising Use of LSD among Business Managers. Substance Use & Misuse 2024
- Psychiatric Residents' Perspectives on Psychedelics and Psychedelic Assisted Therapy. Journal of Psychoactive Drugs July 2, 2025
- Do undergraduates’ views of psychedelics relate to the context for psychedelic use? Drug Science, Policy and Law March 1, 2025
Cites 15
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Journal of Psychopharmacology September 11, 2014
- Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial Psychological Medicine June 15, 2018
- The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Journal of Psychopharmacology July 19, 2010
and 10 more in the library